EC Number |
Recommended Name |
Source Tissue |
Reference |
---|
1.1.1.141 | 15-hydroxyprostaglandin dehydrogenase (NAD+) |
LNCaP cell |
- |
285939, 740148 |
1.1.1.145 | 3beta-hydroxy-DELTA5-steroid dehydrogenase |
LNCaP cell |
- |
741423 |
1.1.1.146 | 11beta-hydroxysteroid dehydrogenase |
LNCaP cell |
- |
760802, 761757 |
1.1.1.213 | 3alpha-hydroxysteroid 3-dehydrogenase (Re-specific) |
LNCaP cell |
- |
725825 |
1.1.1.22 | UDP-glucose 6-dehydrogenase |
LNCaP cell |
- |
711665 |
1.1.1.239 | 3alpha(17beta)-hydroxysteroid dehydrogenase (NAD+) |
LNCaP cell |
- |
725674, 725825 |
1.1.1.27 | L-lactate dehydrogenase |
LNCaP cell |
lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer |
670443 |
1.1.1.357 | 3alpha-hydroxysteroid 3-dehydrogenase |
LNCaP cell |
- |
740737 |
1.1.1.50 | 3alpha-hydroxysteroid 3-dehydrogenase (Si-specific) |
LNCaP cell |
- |
696786 |
1.1.1.51 | 3(or 17)beta-hydroxysteroid dehydrogenase |
LNCaP cell |
- |
740156, 740329 |
1.1.1.64 | testosterone 17beta-dehydrogenase (NADP+) |
LNCaP cell |
- |
725825, 740162 |
1.1.1.8 | glycerol-3-phosphate dehydrogenase (NAD+) |
LNCaP cell |
mGPDH abundance and activity is significantly elevated in prostate cancer cell lines when compared to the normal prostate epithelial cell line PNT1A |
667415 |
1.1.5.3 | glycerol-3-phosphate dehydrogenase |
LNCaP cell |
- |
760855 |
1.13.11.34 | arachidonate 5-lipoxygenase |
LNCaP cell |
- |
657765 |
1.13.11.71 | carotenoid-9',10'-cleaving dioxygenase |
LNCaP cell |
- |
745753 |
1.14.11.16 | peptide-aspartate beta-dioxygenase |
LNCaP cell |
- |
764407 |
1.14.11.65 | [histone H3]-dimethyl-L-lysine9 demethylase |
LNCaP cell |
- |
744413, 754938 |
1.14.11.67 | [histone H3]-trimethyl-L-lysine4 demethylase |
LNCaP cell |
- |
744413 |
1.14.14.18 | heme oxygenase (biliverdin-producing) |
LNCaP cell |
- |
734274 |
1.14.14.32 | 17alpha-hydroxyprogesterone deacetylase |
LNCaP cell |
- |
745754 |
1.14.15.18 | calcidiol 1-monooxygenase |
LNCaP cell |
epidermal growth factor does not upregulate 1alpha-OHase promoter activity in the carcinogenic prostate cells. Dysregulation of 1alpha-OHase in cancer cells may lead to the aberrant growth of prostate cancer cells |
684478 |
1.14.15.18 | calcidiol 1-monooxygenase |
LNCaP cell |
prostate cancer cell line, greatly decreased activity of 25-hydroxyvitamin D-1alpha-hydroxylase due to decreased RNA transcription |
659943 |
1.14.18.B1 | 5,6-dihydroxyindole-2-carboxylic acid oxidase |
LNCaP cell |
- |
744413 |
1.14.99.29 | deoxyhypusine monooxygenase |
LNCaP cell |
- |
727927 |
1.2.1.36 | retinal dehydrogenase |
LNCaP cell |
expresses endogenous RDH13 at high levels |
686690 |
1.3.1.1 | dihydropyrimidine dehydrogenase (NAD+) |
LNCaP cell |
- |
685782 |
1.3.1.124 | 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] |
LNCaP cell |
- |
759825 |
1.3.1.22 | 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) |
LNCaP cell |
- |
-, 726288, 740941, 763398 |
1.3.1.22 | 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) |
LNCaP cell |
prostate cancer cell line |
655182 |
1.3.3.3 | coproporphyrinogen oxidase |
LNCaP cell |
- |
672822, 745755 |
1.3.99.5 | 3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) |
LNCaP cell |
- |
713080, 713449, 740834 |
1.3.99.5 | 3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) |
LNCaP cell |
enzyme-positive prostate cancer cell line, enzyme can be lost in long-term culture |
669566 |
1.3.99.5 | 3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) |
LNCaP cell |
no expression of enzyme isoform II |
670032 |
1.5.3.13 | N1-acetylpolyamine oxidase |
LNCaP cell |
androgen-treated and untreated prostate adenocarcinoma cells |
703028 |
1.5.8.3 | sarcosine dehydrogenase |
LNCaP cell |
- |
743612, 743719 |
2.1.1.20 | glycine N-methyltransferase |
LNCaP cell |
- |
734506 |
2.1.1.319 | type I protein arginine methyltransferase |
LNCaP cell |
- |
756861 |
2.1.1.364 | [histone H3]-lysine4 N-methyltransferase |
LNCaP cell |
- |
759776 |
2.3.1.13 | glycine N-acyltransferase |
LNCaP cell |
- |
758269 |
2.3.1.26 | sterol O-acyltransferase |
LNCaP cell |
- |
706580 |
2.3.1.48 | histone acetyltransferase |
LNCaP cell |
- |
685667 |
2.3.1.5 | arylamine N-acetyltransferase |
LNCaP cell |
- |
672920 |
2.3.1.5 | arylamine N-acetyltransferase |
LNCaP cell |
a prostate cancer cell line |
672920 |
2.3.1.57 | diamine N-acetyltransferase |
LNCaP cell |
- |
756851 |
2.3.1.68 | glutamine N-acyltransferase |
LNCaP cell |
- |
758269 |
2.3.1.85 | fatty-acid synthase system |
LNCaP cell |
- |
704079, 705999 |
2.3.1.85 | fatty-acid synthase system |
LNCaP cell |
at clinically relevant levels, inhibits FASN mRNA, protein expression and enzymatic activity in prostate cancer cells |
676932 |
2.3.3.8 | ATP citrate synthase |
LNCaP cell |
- |
735620 |
2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
LNCaP cell |
- |
673873, 735617 |
2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
LNCaP cell |
core 2 N-acetylglucosaminyltransferase is downregulated in galectin-1-resistant PSA-LNCaP cells compared with galectin-1-sensitive PSA+ LNCaP cells |
685948 |
2.4.1.149 | N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase |
LNCaP cell |
- |
706504 |
2.4.1.155 | alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase |
LNCaP cell |
- |
690452 |
2.4.1.17 | glucuronosyltransferase |
LNCaP cell |
- |
673353, 693011 |
2.4.1.17 | glucuronosyltransferase |
LNCaP cell |
low activity, UGT2B4 |
673353 |
2.4.1.17 | glucuronosyltransferase |
LNCaP cell |
low activity, UGT2B7 |
673353 |
2.4.1.17 | glucuronosyltransferase |
LNCaP cell |
UGT2B10 |
673353 |
2.4.1.17 | glucuronosyltransferase |
LNCaP cell |
UGT2B17 |
673353 |
2.4.2.12 | nicotinamide phosphoribosyltransferase |
LNCaP cell |
- |
723576 |
2.4.2.26 | protein xylosyltransferase |
LNCaP cell |
XT-I mRNA is not expressed but XT-II mRNA |
702090 |
2.4.2.28 | S-methyl-5'-thioadenosine phosphorylase |
LNCaP cell |
- |
736923 |
2.7.1.105 | 6-phosphofructo-2-kinase |
LNCaP cell |
- |
730530 |
2.7.1.105 | 6-phosphofructo-2-kinase |
LNCaP cell |
PFKFB4 is overexpressed in human cancers |
730530 |
2.7.1.137 | phosphatidylinositol 3-kinase |
LNCaP cell |
- |
707969 |
2.7.1.91 | sphingosine kinase |
LNCaP cell |
- |
705658, 706448, 723043 |
2.7.1.94 | acylglycerol kinase |
LNCaP cell |
- |
703034 |
2.7.10.1 | receptor protein-tyrosine kinase |
LNCaP cell |
Ron is highly expressed |
690303 |
2.7.11.10 | IkappaB kinase |
LNCaP cell |
- |
692494 |
2.7.11.11 | cAMP-dependent protein kinase |
LNCaP cell |
- |
708764 |
2.7.11.16 | G-protein-coupled receptor kinase |
LNCaP cell |
- |
737975 |
2.7.11.18 | myosin-light-chain kinase |
LNCaP cell |
LNCaP cells express both long (non-muscle) and short (smooth muscle) isoforms of MLCK |
709713 |
2.7.11.21 | polo kinase |
LNCaP cell |
- |
760980 |
2.7.11.22 | cyclin-dependent kinase |
LNCaP cell |
- |
722123 |
2.7.11.22 | cyclin-dependent kinase |
LNCaP cell |
CDK5 together with p35 |
679026 |
2.8.2.15 | steroid sulfotransferase |
LNCaP cell |
- |
738102 |
2.8.2.2 | alcohol sulfotransferase |
LNCaP cell |
- |
675680, 761662, 761881 |
2.8.2.4 | estrone sulfotransferase |
LNCaP cell |
- |
676931 |
3.1.3.16 | protein-serine/threonine phosphatase |
LNCaP cell |
prostate cancer cell line |
664287 |
3.1.3.4 | phosphatidate phosphatase |
LNCaP cell |
LPP1 |
680546 |
3.1.3.46 | fructose-2,6-bisphosphate 2-phosphatase |
LNCaP cell |
- |
714090, 729519, 730530 |
3.1.3.66 | phosphatidylinositol-3,4-bisphosphate 4-phosphatase |
LNCaP cell |
- |
714648, 751762, 752313 |
3.1.4.12 | sphingomyelin phosphodiesterase |
LNCaP cell |
- |
678375 |
3.1.4.54 | N-acetylphosphatidylethanolamine-hydrolysing phospholipase D |
LNCaP cell |
- |
708945 |
3.1.6.2 | steryl-sulfatase |
LNCaP cell |
human prostate cancer cells with mutated androgen receptor, as is typical for many human prostate tumors |
690441 |
3.3.2.10 | soluble epoxide hydrolase |
LNCaP cell |
- |
709899 |
3.3.2.9 | microsomal epoxide hydrolase |
LNCaP cell |
- |
732299 |
3.4.11.2 | membrane alanyl aminopeptidase |
LNCaP cell |
- |
701038 |
3.4.16.6 | carboxypeptidase D |
LNCaP cell |
- |
732850 |
3.4.17.1 | carboxypeptidase A |
LNCaP cell |
- |
704669 |
3.4.17.21 | Glutamate carboxypeptidase II |
LNCaP cell |
- |
656377, 683948, 707973, 707988, 708256, 709440, 709648, 709808, 709812, 710006, 710007, 710458, 710460 |
3.4.17.21 | Glutamate carboxypeptidase II |
LNCaP cell |
lymph node metastasis prostate cancer cells |
708325 |
3.4.17.21 | Glutamate carboxypeptidase II |
LNCaP cell |
originating from a prostate cancer lymph node metastasis |
668154, 670219 |
3.4.17.21 | Glutamate carboxypeptidase II |
LNCaP cell |
prostate cancer cell line |
656634 |
3.4.17.21 | Glutamate carboxypeptidase II |
LNCaP cell |
quantitative expression analysis |
670740 |
3.4.17.21 | Glutamate carboxypeptidase II |
LNCaP cell |
subline C4-2 |
709649 |
3.4.21.106 | hepsin |
LNCaP cell |
- |
650769, 674067, 718105 |
3.4.21.106 | hepsin |
LNCaP cell |
used as positive control |
674067 |
3.4.21.109 | matriptase |
LNCaP cell |
- |
683047, 690452 |
3.4.21.109 | matriptase |
LNCaP cell |
expression determined by quantitative RT-PCR |
707437 |
3.4.21.122 | transmembrane protease serine 2 |
LNCaP cell |
- |
752699, 753229 |
3.4.21.73 | u-Plasminogen activator |
LNCaP cell |
silencing of transmembrane protein Notch1 by siRNA results in significant reduction in the expression of uPA and matrix metalloproteinase-9 gene transcripts. Knock-down of Notch also reduces the mRNA expression and protein levels of uPA and matrix metalloproteinase-9 |
697383 |